Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted radionuclide therapy for neuroendocrine tumours.

V J Lewington1

  • 1Nuclear Medicine, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK. vjlweington@hotmail.com

Endocrine-Related Cancer
|January 10, 2004
PubMed
Summary

Targeted radiotherapy offers an effective systemic treatment for neuroendocrine tumors, especially for inoperable or widespread disease. This approach shows low toxicity and requires specific imaging and patient function criteria for success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A practical guide to targeted therapy for bone pain palliation.

Nuclear medicine communications·2002
Same author

Isotopic evaluation and therapy in patients with malignant endocrine disease.

Best practice & research. Clinical endocrinology & metabolism·2001
Same author

Guidelines for the provision of physics support to nuclear medicine. Report of a Joint Working Group of the British Institute of Radiology, British Nuclear Medicine Society.

Nuclear medicine communications·1999
Same author

Radionuclide therapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·1999
Same author

Radionuclide therapy.

Nuclear medicine communications·1999
Same author

Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee.

European journal of nuclear medicine·1999

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiotherapy

Background:

  • Neuroendocrine tumors (NETs) present complex management challenges, particularly in advanced stages.
  • Targeted radiotherapy has emerged as a promising systemic treatment modality for NETs.

Purpose of the Study:

  • To review the current evidence and clinical experience of targeted radiotherapy in managing neuroendocrine tumors.
  • To discuss the established (131)I metaiodobenzylguanidine therapy and emerging radiolabeled peptide therapies.

Main Methods:

  • Review of clinical experience and published data on targeted radiotherapy for neuroendocrine tumors.
  • Focus on therapies like (131)I metaiodobenzylguanidine, (90)Y DOTATOC, and (90)Y lanreotide.
  • Assessment of treatment prerequisites, including diagnostic imaging and patient's physiological status.

Related Experiment Videos

Main Results:

  • Targeted radiotherapy is effective for inoperable or multi-site neuroendocrine tumors.
  • Treatment toxicity is generally low, primarily reversible myelosuppression and potential nephrotoxicity.
  • Successful treatment relies on high tumor uptake on imaging and stable patient function.

Conclusions:

  • Targeted radiotherapy, including (131)I MIBG and radiolabeled peptides, is a valuable systemic option for neuroendocrine tumors.
  • Careful patient selection based on imaging and function is crucial for optimal outcomes.
  • Further research is warranted to explore future directions in this field.